Le Lézard
Classified in: Health, Business
Subjects: LEG, SBS, AVO, CFG

STATEMENT - CFIB statement on adoption of Bill C-2 and Bill C-3


TORONTO, Dec. 17, 2021 /CNW/ - While the Canadian Federation of Independent Business (CFIB) is pleased that the federal government has passed Bill C-2 into law allowing some businesses to receive ongoing pandemic support, we remain deeply concerned that the majority of small firms in need of help will not qualify. The Tourism and Hospitality Recovery and the Hardest-Hit Business Recovery Programs can be vital lifelines, especially as businesses in many sectors face renewed uncertainty and possible additional restrictions with the rise of the Omicron variant.

A full 80 per cent of small firms in need of financial support will no longer qualify for wage or rent subsidies due to the new programs' high thresholds. CFIB is urging the federal government to lower the threshold for all wage and rent supports and raise the subsidy levels for all businesses to the formula used for the Tourism and Hospitality Recovery Program. Businesses that started after the pandemic began should be allowed to access all federal support programs.

CFIB is also concerned about the adoption of Bill C-3 which mandates 10 employer-paid sick days for employees of federally regulated businesses. Only 36 per cent of small businesses have returned to their pre-pandemic sales levels, and one in five (22 per cent) of those who haven't say they can survive less than six months at their current level of revenue loss. Border closures, new or rumoured capacity restrictions, and vaccine passport requirements all ensure that most of those businesses will not see normal sales levels for many months. They simply cannot take on additional costs at this time.

As long as there are COVID-related restrictions imposed on their activities businesses should have access to government support programs and governments should do everything possible to avoid imposing cost increases.

Small business owners can sign CFIB's petition calling on the government to extend the federal support programs at cfib.ca/covidpetition.

- Corinne Pohlmann, Senior Vice-President, National Affairs, Canadian Federation of Independent Business (CFIB)
- Jasmin Guenette, Vice-President, National Affairs

About CFIB
The Canadian Federation of Independent Business (CFIB) is Canada's largest association of small and medium-sized businesses with 95,000 members across every industry and region. CFIB is dedicated to increasing business owners' chances of success by driving policy change at all levels of government, providing expert advice and tools, and negotiating exclusive savings. Learn more at cfib.ca.

SOURCE Canadian Federation of Independent Business


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: